ACAD Stock Recent News

Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.

Here is how Acadia Pharmaceuticals (ACAD) and Medpace (MEDP) have performed compared to their sector so far this year.

Biotech is still one of the most exciting sectors on the market. Recession-proof, the sector is still thriving with millions of retiring baby boomers, mergers and acquisitions, new innovation, the introduction of artificial intelligence with drug discovery and demand for new treatments.

Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Jessica Tieszen - Associate Director of Investor Relations Albert Kildani - Senior Vice President, Investor Relations & Corporate Communications Steve Davis - Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Doug Williamson - Head of Research & Development Mark Schneyer - Chief Financial Officer Parag Meswani - Senior Vice President: Trofinetide, Rare Diseases Franchise Kathie Bishop - Head of Rare Diseases & External Innovation Conference Call Participants Ritu Baral - TD Cowen Tessa Romero - J.P. Morgan Yatin Suneja - Guggenheim Charles Duncan - Cantor Fitzgerald Tazeen Ahmad - Bank of America Sumant Kulkarni - Canaccord Genuity Ami Fadia - Needham & Company Jay Olson - Oppenheimer Operator Good day ladies and gentlemen and welcome to ACADIA Pharmaceuticals Third Quarter 2023 Financial Results Conference Call.

Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever.

An analyst upgraded Acadia Pharmaceuticals shares today. As a result, investors are bidding the stock up in morning trading.

September hasn't been overly kind to growth stocks. This latest bout of volatility, however, may have created some compelling buying opportunities.

Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.